Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs

Molecular Therapy

Volumn 8, Issue 2, 2003, Pages 196-206

  Li, Ming Jie ^a   Bauer, Gerhard ^a   Michienzi, Alessandro ^a   Yee, Jiing Kuan ^a   Lee, Nan Sook ^a   Kim, James ^a   Li, Shirley ^a   Castanotto, Daniela ^a   Zaia, John ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CCR5; HIV 1 gene therapy; Lentiviral vector; Ribozyme; RNA decoy; siRNAs; TAR

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; LENTIVIRUS VECTOR; RIBOZYME; RNA POLYMERASE; SMALL NUCLEOLAR RNA; TRANSACTIVATOR PROTEIN; VIRUS RNA;

ADENOVIRUS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL DIVISION; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENCY; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; MEMBRANE TRANSPORT; MONOCYTE; MONONUCLEAR CELL; PROMOTER REGION; PROTEIN EXPRESSION; STEM CELL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 10744228940     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00165-5     Document Type: Article

References (73)

1. + T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
2. Palella, F. J. Jr, et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338: 853-860.
3. Ho, D. D. (1998). Toward HIV eradication or remission: the tasks ahead. Science 280: 1866-1867.
4. Kasten, S., et al. (2000). Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur. J. Med. Res. 5: 323-328.
5. Martinez-Picado, J., et al. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97: 10948-10953.
6. Winters, M. A., et al. (2000). Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antiviral Ther. 5: 57-63.
7. Bacheler, L. T., et al. (2000). Human immunodeficiency virus type 1 mutations selected in patients failing Efavirenz combination therapy. Antimicrob. Agents Chemother. 44: 2475-2484.
8. Domburg, R., and Pomerantz, R. J. (2000). HIV-1 gene therapy: promise for the future. Adv. Pharmacol. 49: 229-261.
9. Kohn, D. B. (1999). Gene therapy using hematopoietic stem cells. Curr. Opin. Mol. Ther. 1: 437-442.
10. Macpherson, J. L., Ely, J. A., Sun, L. Q., and Symonds, G. P. (1999). Ribozymes in gene therapy of HIV-1. Front. Biosci. 4: D497-505.
11. Rossi, J. J. (1999). The application of ribozymes to HIV infection. Curr. Opin. Mol. Ther. 1: 316-322.
12. Statham, S., and Morgan, R. A. (1999). Gene therapy clinical trials for HIV. Curr. Opin. Mol. Ther. 1: 430-436.
13. Woods, N. B., Ooka, A., and Karlsson, S. (2002). Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia 16: 563-569.
14. Leiden, J. M. (1995). Gene therapy - Promise, pitfalls, and prognosis. N. Engl. J. Med. 333: 871-873.
15. Miller, D. G., Adam, M. A., and Miller, A. D. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10: 4239-4242.
16. Verma, I. M. (1994). Gene therapy: hopes, hypes, and hurdles. Mol. Med. 1: 2-3.
17. Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93: 11382-11388.
18. Naldini, L., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
19. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
20. Blomer, U., Naldini, L., Kafri, T., Trono, D., Verma, I. M., and Gage, F. H. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71: 6641-6649.
21. Galimi, F., and Verma, I. M. (2002). Opportunities for the use of lentiviral vectors in human gene therapy. Curr. Top. Microbiol. Immunol. 261: 245-254.
22. Romano, G., and Giordano, A. (2000). Gene therapy after decade of clinical trials. Clin. Ther. 151: 63-64.
23. Romano, G., Michell, P., Pacilio, C., and Giordano, A. (2000). Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18: 19-39.
24. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89: 2259-2267.
25. Lisziewicz, J., Zeng, G., Gratas, C., Weinstein, J. N., and Lori, F. (2000). Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule. Hum. Gene Ther. 11: 807-815.
26. Cagnon, L., and Rossi, J. J. (2000). Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev. 10: 251-261.
27. Michienzi, A., Li, S., Zaia, J. A., and Rossi, J. J. (2002). A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. USA 99: 14047-14052.
28. Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
29. Deng, H., et al. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
30. Dean, M., et al. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
31. Liu, R., et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
32. Huang, Y., et al. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2: 1240-1243.
33. Michael, N. L., Louie, L. G., and Sheppard, H. W. (1997). CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 350: 741-742.
34. Arya, S. K., Guo, C., Josephs, S. F., and Wong-Staal, F. (1985). Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229: 69-73.
35. Dingwall, C., et al. (1990). HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 9: 4145-4153.
36. Lisziewicz, J., et al. (1993). Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. USA 90: 8000-8004.
37. Michienzi, A., Cagnon, L., Bahner, I., and Rossi, J. J. (2000). Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc. Natl. Acad. Sci. USA 97: 8955-8960.
38. Sullenger, B. A., and Cech, T. R. (1993). Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262: 1566-1569.
39. Marasco, W. A., Szilvay, A. M., Kalland, K. H., Helland, D. G., Reyes, H. M., and Walter, R. J. (1994). Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch. Virol. 139: 133-154.
40. Ruben, S., et al. (1989). Structural and functional characterization of human immuno-deficiency virus tat protein. J. Virol. 63: 1-8.
41. Kuppuswamy, M., Subramanian, T., Srinivasan, A., and Chinnadurai, G. (1989). Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res. 17: 3551-3561.
42. Dang, C. V., and Lee, W. M. (1989). Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. J. Biol. Chem. 264: 18019-18023.
43. Hannon, G. J. (2002). RNA interference. Nature 418: 244-251.
44. Martinez, J., Nez, M. A., Clotet, B., and Este, J. A. (2002). RNA interference of HIV replication. Trends Immunol. 23: 559-561.
45. Martinez, M. A., et al. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16: 2385-2390.
46. Park, W. S., et al. (2002). Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res. 30: 4830-4835.
47. Capodici, J., Kariko, K., and Weissman, D. (2002). Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol. 169: 5196-5201.
48. Lin, S. L., and Ying, S. Y. (2001). D-RNAi (messenger RNA-antisense DNA interference) as a novel defense system against cancer and viral infections. Curr. Cancer Drug Targets 1: 241-247.
49. Coburn, G. A., and Cullen, B. R. (2002). Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76: 9225-9231.
50. Jacque, J. M., Triques, K., and Stevenson, M. (2002). Modulation of HIV-1 replication by RNA interference. Nature 418: 435-438.
51. Lawrence, D. (2002). RNAi could hold promise in the treatment of HIV. Lancet 359: 2007.
52. Lee, N. S., et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20: 500-505.
53. Novina, C. D., et al. (2002). siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8: 681-686.
54. Good, P. D., et al. (1997). Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. 4: 45-54.
55. Castanotto, D., Li, H., and Rossi, J. J. (2002). Functional siRNA expression from transfected PCR products. RNA 8: 1454-1460.
56. + T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69: 3712-3720.
57. Graham, F. L., and van der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456-467.
58. Gasmi, M., Glynn, J., Jin, M. J., Jolly, D. J., Yee, J. K., and Chen, S. T. (1999). Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J. Virol. 73: 1828-1834.
59. Raport, C. J., Gosling, J., Schweickart, V. L., Gray, P. W., and Charo, I. F. (1996). Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1 beta, and MIP-1 alpha. J. Biol. Chem. 271: 17161-17166.
60. Barcellini-Couget, S., Fenard, D., Bertrand, E., Singer, R. H., Lefebvre, J. C., and Doglio, A. (1998). 3′-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes. Antisense Nucleic Acid Drug Dev. 8: 379-390.
61. Roe, T., Reynolds, T: C., Yu, G., and Brown, P. O. (1993). Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12: 2099-2108.
62. Lewis, P. F., and Emerman, M. (1994). Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68: 510-516.
63. + cells via human immunodeficiency virus-based gene transfer vectors. Hum. Gene Ther. 10: 935-945.
64. - cell transduction via lentivirus-based gene transfer vectors. Hum. Gene Ther. 10: 1479-1489.
65. Qin, X. F., An, D. S., Chen, I. S., and Baltimore, D. (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 100: 183-188.
66. Ferguson, M. R., Rojo, D. R., von Lindern, J. J., and O'Brien, W. A. (2002). HIV-1 replication cycle. Clin. Lab. Med. 22: 611-635.
67. Yamamoto, T., et al. (2002). Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replication. Microbiol. Immunol. 46: 809-817.
68. Jia, Q., and Sun, R. (2003). Inhibition of gammaherpesvirus replication by RNA interference. J. Virol. 77: 3301-3306.
69. Sui, G., Soohoo, C., el Affar, B., Gay, F., Shi, Y., and Forrester, W. C. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99: 5515-5520.
70. Caplen, N. J., Zheng, Z., Falgout, B., and Morgan, R. A. (2002). Inhibition of viral gene expression and replication in mosquito cells by dsRNA-triggered RNA interference. Mol. Ther. 6: 243-251.
71. Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R., and Bushman, F. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
72. Tarantal, A. F., et al. (2001). Lentiviral vector gene transfer into fetal rhesus monkeys (Macaca mulatta): lung-targeting approaches. Mol. Ther. 4: 614-621.
73. Tarantal, A. F., et al. (2001). Rhesus monkey model for fetal gene transfer: studies with retroviral-based vector systems. Mol. Ther. 3: 128-138.